Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00241007 |
SAFETY EXTENSION STUDY TO THE CORE STUDY CVAH631C2301
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension |
Estimated Enrollment: | 797 |
Study Start Date: | December 2003 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
SUCCESSFUL COMPLETION OF STUDY CVAH631C2301
-
Exclusion Criteria:
United States, New Jersey | |
Novartis Pharmaceuticals | |
East Hanover, New Jersey, United States, 07936 | |
Novartis Pharmaceuticals | |
East Hanover, New Jersey, United States, 07936 |
Study Chair: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Study ID Numbers: | CVAH631C2301E1 |
Study First Received: | October 14, 2005 |
Last Updated: | June 1, 2006 |
ClinicalTrials.gov Identifier: | NCT00241007 History of Changes |
Health Authority: | United States: Food and Drug Administration |
HYPERTENSION, VALSARTAN |
Sodium Chloride Symporter Inhibitors Diuretics Vascular Diseases Cardiovascular Agents |
Antihypertensive Agents Hydrochlorothiazide Valsartan Hypertension |
Molecular Mechanisms of Pharmacological Action Diuretics Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Vascular Diseases Cardiovascular Agents Antihypertensive Agents Hydrochlorothiazide |
Pharmacologic Actions Membrane Transport Modulators Natriuretic Agents Therapeutic Uses Cardiovascular Diseases Valsartan Hypertension |